Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Loratadine-ambroxol pharmaceutical composite and liposome solid preparation thereof

A technology of loratadine and solid preparation, which is applied in the field of medicine to achieve the effects of reducing drug toxicity, improving quality and reducing drug side effects

Inactive Publication Date: 2010-01-20
HAINAN YONGTIAN PHARMA INST
View PDF7 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no drug for the treatment of multiple symptoms caused by respiratory allergies at the same time in China

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Loratadine-ambroxol pharmaceutical composite and liposome solid preparation thereof
  • Loratadine-ambroxol pharmaceutical composite and liposome solid preparation thereof
  • Loratadine-ambroxol pharmaceutical composite and liposome solid preparation thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] Example 1 The preparation of the liposome of loratadine ambroxol pharmaceutical composition

[0051] prescription:

[0052] Loratadine 5g

[0053] Ambroxol Hydrochloride 25g

[0054] Egg yolk lecithin 30g

[0055] Cholesterol 15g

[0056] Sodium deoxycholate 7.5g

[0057] Poloxamer 188 20g

[0058] Preparation Process

[0059] (1) Dissolve 30g of egg yolk lecithin, 15g of cholesterol, 7.5g of sodium deoxycholate and 20g of poloxamer 188 in 450ml of isopropanol and methanol at a volume ratio of 2:1, mix well, and place on a rotary thin film evaporator Isopropanol and methanol were removed under reduced pressure to obtain a phospholipid film;

[0060] (2) Add 200ml of acetic acid-sodium acetate buffer solution with pH=4.8, stir to completely hydrate the phospholipid film, then homogenize and emulsify with a tissue grinder for 20min at a speed of 14000r / min, to prepare a blank liposome suspension; (Loratadine 5g is 1 part, buffer solution 200ml is 200g is 40 par...

Embodiment 2

[0079] Example 2 The preparation of the liposome of loratadine ambroxol pharmaceutical composition

[0080] prescription:

[0081] Loratadine 5g

[0082] Ambroxol Hydrochloride 25g

[0083] Egg Yolk Lecithin 90g

[0084] Cholesterol 40g

[0085] Sodium deoxycholate 20g

[0086] Poloxamer 188 45g

[0087] Preparation Process

[0088] (1) 90g egg yolk lecithin, 40g cholesterol, 20g sodium deoxycholate and 45g poloxamer 188 were dissolved in 1900ml of isopropanol and methanol with a volume ratio of 2:1, mixed evenly, and reduced on a rotary thin film evaporator. Remove isopropanol and methanol under pressure to obtain a phospholipid film;

[0089] (2) Add 1000ml of citric acid-sodium citrate buffer solution with pH = 6.2, stir to completely hydrate the phospholipid membrane, then homogenize and emulsify for 15min with a tissue masher at a speed of 12000r / min to prepare blank liposomes suspension;

[0090] (3) Evenly disperse 5g of loratadine and 25g of ambroxol hydro...

Embodiment 3

[0103] Example 3 The preparation of the tablet of loratadine ambroxol pharmaceutical composition

[0104] Select the loratadine ambroxol medicine 30g of embodiment 1 (containing loratadine 5g, ambroxol hydrochloride 25g)

[0105] Composition of liposomes

[0106] Microcrystalline Cellulose 56g

[0107] Mannitol 35g

[0108] Croscarmellose Sodium 6.5g

[0109] Hypromellose 0.6g

[0110] Magnesium Stearate 1.3g

[0111] Preparation Process

[0112] (1) the liposome of the 30g loratadine ambroxol pharmaceutical composition prepared by embodiment 1 is pulverized, crosses 80 mesh sieves, and is subsequent use;

[0113] (2) Take by weighing 56g microcrystalline cellulose, 35g mannitol, 6.5g croscarmellose sodium, cross 80 mesh sieves, mix, and set aside;

[0114] (3) Mix the above-mentioned raw and auxiliary materials evenly, add 30 ml of 2% hypromellose 50% ethanol solution to make soft materials, pass through a 20-mesh sieve to granulate, dry at 65 ° C, and granulate th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a loratadine-ambroxol pharmaceutical composite and a liposome solid preparation thereof and a preparation method thereof; the liposome comprises the following components according to the parts by weight percent: 1 part of loratadine, 5 parts of ambroxol hydrochloride, 3-30 parts of yolk lecithin, 1-14 of cholesterol, 1.2-10 parts of sodium deoxycholate and 3-18 parts of poloxamer 188.

Description

technical field [0001] The invention relates to a liposome solid preparation of a pharmaceutical composition containing loratadine ambroxol and a preparation method thereof, belonging to the technical field of medicine. Background technique [0002] Respiratory system diseases account for about 1 / 4 of internal medicine patients. In my country's population statistics, respiratory system diseases are the second cause of death. The main symptoms of respiratory diseases are cough, expectoration and asthma, but there are not many drugs available clinically, and the onset of effect is slow. [0003] Loratadine is an oral long-acting tricyclic antihistamine with selective anti-peripheral H1 receptor effects. Clinically, it is mostly used to treat allergic rhinitis. It has good clinical effect on alleviating symptoms related to allergic rhinitis, such as sneezing, runny nose, nasal itching, nasal congestion, eye itching and burning sensation. Loratadine (absorbed through the gastr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4545A61K31/137A61K9/127A61K9/00A61K9/20A61J3/00A61J3/10A61P11/00A61P37/08
Inventor 王明
Owner HAINAN YONGTIAN PHARMA INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com